2 results
Approved WMOCompleted
To compare the efficacy of two different techniques for the augmentation of the atrophic maxilla.
Approved WMOPending
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.